MedWatch

Chinese dispensation allows ALK to file for registration

Allergy company ALK can now take a large step on the road to getting its dust mite allergy tablet, Acarizax, approved on the Chinese market.

Photo: ALK / PR

ALK is now positioned to file for Chinese regulatory approval of its tablet Acarizax, a dust mite allergy treatment, following the issue of a waiver by country’s health authorities, a company press release announced on Thursday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs